Novo Nordisk has dismissed its patent infringement lawsuit against telehealth provider Hims & Hers, following an agreement that will see the pharmaceutical giant’s branded weight loss medications sold through the Hims platform.
The news sent shares of Hims & Hers Health Inc. soaring by more than 40% in Monday morning trading.